Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMAHA-01A: MK-5684-based therapies in metastatic castration-resistant prostate cancer
2023-506288-33-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 2, open-label trial of opevesostat, cabazitaxel, olaparib and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more dose-limiting toxicities, Number of participants who experience one or more adverse events and 2 more. Planned start Aug 2024; status: authorised.
02
Drugs
opevesostatcabazitaxelolaparibdocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2023-506288-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506288-33-00.